Results from a pooled analysis of two European, randomized, placebo-controlled, phase 3 studies of ATX-101 for the pharmacologic reduction of excess submental fat.

The responses were consistently superior with ATX-101 compared with the placebo for the different age groups, except for the patients 18–30 years of age receiving ATX-101 1 mg/cm 2 , in which the difference did not reach statistical significance.

also in 111,027 other papers